PL2400954T3 - Sposób wytwarzania stałych, doustnych postaci solifenacyny i jej farmaceutycznie dopuszczalnych soli - Google Patents

Sposób wytwarzania stałych, doustnych postaci solifenacyny i jej farmaceutycznie dopuszczalnych soli

Info

Publication number
PL2400954T3
PL2400954T3 PL10705984T PL10705984T PL2400954T3 PL 2400954 T3 PL2400954 T3 PL 2400954T3 PL 10705984 T PL10705984 T PL 10705984T PL 10705984 T PL10705984 T PL 10705984T PL 2400954 T3 PL2400954 T3 PL 2400954T3
Authority
PL
Poland
Prior art keywords
solifenacin
pharmaceutically acceptable
acceptable salts
dosage forms
oral dosage
Prior art date
Application number
PL10705984T
Other languages
English (en)
Inventor
Miha Vrbinc
Franc Vrecer
Urska Turk
Urska Jursic
Original Assignee
Krka, D.D., Novo Mesto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42041747&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2400954(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Krka, D.D., Novo Mesto filed Critical Krka, D.D., Novo Mesto
Publication of PL2400954T3 publication Critical patent/PL2400954T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL10705984T 2009-02-27 2010-03-01 Sposób wytwarzania stałych, doustnych postaci solifenacyny i jej farmaceutycznie dopuszczalnych soli PL2400954T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SI200900056 2009-02-27
SI200900159 2009-06-08
EP10705984.2A EP2400954B2 (en) 2009-02-27 2010-03-01 Process for forming solid oral dosage forms of solifenacin succinate

Publications (1)

Publication Number Publication Date
PL2400954T3 true PL2400954T3 (pl) 2017-04-28

Family

ID=42041747

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10705984T PL2400954T3 (pl) 2009-02-27 2010-03-01 Sposób wytwarzania stałych, doustnych postaci solifenacyny i jej farmaceutycznie dopuszczalnych soli

Country Status (9)

Country Link
EP (1) EP2400954B2 (pl)
DK (1) DK2400954T3 (pl)
EA (1) EA023529B1 (pl)
ES (1) ES2609061T3 (pl)
HR (1) HRP20161730T1 (pl)
HU (1) HUE030376T2 (pl)
PL (1) PL2400954T3 (pl)
SI (1) SI2400954T1 (pl)
WO (1) WO2010097243A2 (pl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011137877A2 (en) * 2010-05-07 2011-11-10 Zentiva K.S. A pharmaceutical composition containing solifenacin and a method of its manufacture
EP2500013B1 (en) 2011-03-15 2019-10-02 Alfred E. Tiefenbacher (GmbH & Co. KG) Pharmaceutical composition comprising solifenacin
EP2778167A1 (en) 2013-03-11 2014-09-17 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Stable pharmaceutical composition comprising amorphous solifenacin or its pharmaceutically acceptable salt
KR20150092385A (ko) * 2014-02-03 2015-08-13 씨제이헬스케어 주식회사 솔리페나신을 포함하는 안정한 제제 및 이의 제조방법
CN104940152B (zh) * 2014-03-31 2017-12-29 成都国为生物医药有限公司 一种含有琥珀酸索利那新的药物组合物
CN105012961B (zh) * 2014-04-17 2020-07-21 燃点(南京)生物医药科技有限公司 稳定的药物组合物及其制备方法
WO2015170237A1 (en) * 2014-05-05 2015-11-12 Torrent Pharmaceuticals Limited Stable solifenacin composition
CN105362245A (zh) * 2014-08-30 2016-03-02 山东中泰药业有限公司 含有索利那新的片剂组合物及其制备方法
CN104523628B (zh) * 2014-12-24 2017-08-25 乐普药业股份有限公司 一种可粉末直接压片的琥珀酸索利那新片剂及其制备方法
WO2017021482A1 (en) * 2015-08-05 2017-02-09 Interquim, S.A. Rivaroxaban pharmaceutical compositions
CN105395494A (zh) * 2015-11-27 2016-03-16 浙江华义医药有限公司 一种含琥珀酸索利那新的药物组合物及其制备方法
EP3666261B1 (en) * 2017-08-08 2025-01-15 Mitsubishi Chemical Corporation Pharmaceutical tablet and method for producing same
KR101977890B1 (ko) * 2018-05-08 2019-05-13 씨제이헬스케어 주식회사 솔리페나신을 포함하는 안정한 제제 및 이의 제조방법

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU508480B2 (en) 1977-04-13 1980-03-20 Asahi Kasei Kogyo Kabushiki Kaisha Microcrystalline cellulose excipient and pharmaceutical composition containing thesame
EP0876814A1 (en) 1997-05-07 1998-11-11 "PHARLYSE", Société Anonyme Dry powder inhaler excipient, process for its preparation and pharmaceutical compositions containing it
JP5168711B2 (ja) * 2004-03-25 2013-03-27 アステラス製薬株式会社 ソリフェナシンまたはその塩の固形製剤用組成物
WO2007072169A2 (en) * 2005-12-20 2007-06-28 Pfizer Products Inc. Pharmaceutical combination for the treatment of luts comprising a pde5 inhibitor and a muscarinic antagonist
US20080114028A1 (en) 2006-07-24 2008-05-15 Tamas Koltai Process for preparing polymorphic forms of solifenacin succinate
EP2146693A2 (en) * 2007-04-11 2010-01-27 Dr. Reddy's Laboratories Ltd. Solifenacin compositions
EP2018850A1 (en) 2007-07-24 2009-01-28 Ratiopharm GmbH Pharmaceutical composition comprising solifenacin or a pharmaceutically acceptable salt thereof
PL3067353T3 (pl) 2008-07-29 2018-04-30 Krka, D.D., Novo Mesto Sposób wytwarzania soli solifenacyny i ich włączenie do farmaceutycznych postaci dawkowania

Also Published As

Publication number Publication date
WO2010097243A2 (en) 2010-09-02
SI2400954T1 (sl) 2017-02-28
HUE030376T2 (en) 2017-05-29
HRP20161730T1 (hr) 2017-02-24
EP2400954A2 (en) 2012-01-04
WO2010097243A3 (en) 2011-06-16
DK2400954T3 (en) 2017-01-16
EA201190161A1 (ru) 2012-02-28
EA023529B1 (ru) 2016-06-30
EP2400954B2 (en) 2024-06-26
ES2609061T3 (es) 2017-04-18
EP2400954B1 (en) 2016-09-28

Similar Documents

Publication Publication Date Title
SI2400954T1 (sl) Postopek za pripravo trdne oralne dozirne oblike solifenacina in njegovih farmacevtsko sprejemljivih soli
ZA200906899B (en) Process for preparation of erlotinib and its pharmaceutically acceptable salts
IL206500A0 (en) Process for the preparation of sitagliptin and pharmaceutically acceptable salts thereof
SI2588090T1 (sl) Trdne peroralne farmacevtske oblike, ki obsegajo dabigatran eteksilat in njegove farmacevtsko sprejemljive soli
PL3363797T3 (pl) Doustna postać dawkowania inhibitorów kinazy regulującej sygnał apoptozy
IL238477A (en) Pharmaceutical dosage form for oral administration of the bcl-2 family inhibitor
IL217755A0 (en) Process for the manufacture of pharmaceutically active compounds
IL231485A (en) Oral dosage forms of medicinal preparations are resistant to abuse
PL3067353T3 (pl) Sposób wytwarzania soli solifenacyny i ich włączenie do farmaceutycznych postaci dawkowania
PL2241553T3 (pl) Sposób syntezy iwabradyny i jej soli addycyjnych z kwasem dopuszczalnym farmaceutycznie
IL223311A0 (en) Oral dosage forms of bendamustine
SI2736909T1 (sl) Proces za pripravo sitagliptina in njegovih farmacevtsko sprejemljivih soli
EP2435052A4 (en) SOLID PHARMACEUTICAL FORMS OF LAMIVUDIN ORAL ADMINISTRATION
SI2536396T1 (sl) Postopek za pripravo oralnih trdnih odmernih oblik, ki obsegajo valsartan
PL2291374T3 (pl) Sposób wytwarzania solifenacyny i/lub jej farmaceutycznie dopuszczalnych soli o wysokiej czystości farmaceutycznej
PT2241554E (pt) Novo processo de síntese da ivabradina e dos seus sais de adição a um ácido aceitável do ponto de vista farmacêutico
HU1000299D0 (en) Nanostructured atorvastatin, its pharmaceutically acceptable salts and pharmaceutical compositions containing them and process for their preparation
EP2121729A4 (en) PHARMACEUTICAL, SUBSTANTIVE SALTS OF THYMODEPRESSINE AND METHOD FOR THE PRODUCTION THEREOF
SI2585051T2 (sl) Farmacevtske oralne odmerne oblike,ki obsegajo lerkanidipin in enalapril in njune farmacevtsko sprejemljive soli
EP2389360A4 (en) METHOD FOR PRODUCING ZOFENOPRIL AND PHARMACEUTICAL ACCEPTIC SALTS THEREFOR
SI2451809T1 (sl) Postopek za pripravo in čiščenje soli solifenacina
ZA201000159B (en) Process for the production of substituted 5-quinolyl-oxazoles and pharmaceutically acceptable salts thereof
SI2607354T1 (sl) Nov postopek sinteze ivabradina in njegovih dodatnih soli s farmacevtsko sprejemljivo kislino
SI2595979T1 (sl) Proces za čiščenje farmacevtsko sprejemljivih soli Escitaloprama
HK1166778A (en) Process for the preparation of erlotinib or its pharmaceutically acceptable salts thereof